Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19971619 | 1.00 | HSD11B1 (0.46) | HSD11B1HPGDTFPI2PREPALDH1A1 | |
| SCHEMBL19971620 | 1.00 | HSD11B1 (0.46) | HSD11B1HPGDTFPI2PREPALDH1A1 | |
| SCHEMBL19971624 | 0.96 | TFPI2 (0.46) | HSD11B1HPGDTFPI2PREPALDH1A1 | |
| SCHEMBL19971622 | 0.96 | TFPI2 (0.46) | HSD11B1HPGDTFPI2PREPALDH1A1 | |
| SCHEMBL19971623 | 0.96 | TFPI2 (0.46) | HSD11B1HPGDTFPI2PREPALDH1A1 | |
| SCHEMBL3725686 | 0.78 | HPGD (0.64) | HSD11B1HPGDALDH1A1TSHRMEN1 | |
| SCHEMBL20585975 | 0.75 | POLB (0.36) | HSD11B1TFPI2ALDH1A1TSHRHSD11B2 | |
| SCHEMBL20585977 | 0.75 | POLB (0.36) | HSD11B1TFPI2ALDH1A1TSHRHSD11B2 | |
| SCHEMBL3106502 | 0.75 | POLB (0.36) | HSD11B1TFPI2ALDH1A1TSHRHSD11B2 | |
| SCHEMBL18036560 | 0.75 | POLB (0.36) | HSD11B1TFPI2ALDH1A1TSHRHSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-08-23 | — | — | US | claimed |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-08-23 | — | — | US | disclosed |
| US-9944613-B2 | Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | HSD11B1 552/4885HPGD 302/4885TFPI2 707/4885 |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | HSD11B1 552/4885HPGD 302/4885TFPI2 707/4885 |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | HSD11B1 552/4885HPGD 302/4885TFPI2 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.